Permanent capital removes the date. That does not make the investor less disciplined — the discipline simply moves from the calendar to the business. The question is no longer "when do we sell" but "is this still the right owner for this company". Often the answer is yes for a very long time. Occasionally it is no, and then a sale is made for the business's reasons rather than the investor's.

The practical effect is that a permanent-capital investor can behave like a founder: patient with growth, impatient with waste, and indifferent to the noise in between.

Having built technology operating companies, the firm reads a technology business differently. It asks who actually pays, how long they stay, what it costs to serve them, and what happens when a well-funded competitor decides the same market is attractive. It is sceptical of growth that is bought and respectful of growth that is earned.

That is not caution for its own sake. Concentrated, long-held positions in technology businesses with real economics have been among the best investments of the past two decades. The point is to find the businesses, not the narratives.

This makes healthcare a natural home for permanent capital. A provider, a service or an enabling technology that needs five years to reach maturity is a poor fit for a fund with a five-year hold, and a good fit for an owner who does not need to sell. The firm looks for businesses with regulatory maturity, evidence-based products and management capable of building across markets, and is prepared to wait for them.